Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 34% Improvement Relative Risk Recovery, day 7, dyspnea 80% Recovery, day 5, dyspnea 58% Recovery, day 7, fever 47% Recovery, day 5, fever 47% Recovery, day 7, sore thr.. 66% Recovery, day 5, sore thr.. 47% Recovery, day 7, cough 30% Recovery, day 5, cough 7% Recovery, day 7, myalgia 21% Recovery, day 5, myalgia 38% c19favipiravir.com Tehrani et al. IRCT20211004052664N1 Favipiravir RCT LATE Favors favipiravir Favors control
Tehrani, 78 patient favipiravir late treatment RCT: 34% lower hospitalization [p=0.24] https://c19p.org/tehrani4
copied to clipboard
Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial
Tehrani et al., Mediterranean Journal of Infection Microbes and Antimicrobials, doi:10.4274/mjima.galenos.2022.2022.30, IRCT20211004052664N1
15 Jun 2022    Source   PDF   Share   Tweet
RCT 78 patients in Iran, showing improved recovery with favipiravir treatment.
risk of hospitalization, 34.2% lower, RR 0.66, p = 0.24, treatment 10 of 38 (26.3%), control 16 of 40 (40.0%), NNT 7.3.
risk of no recovery, 79.6% lower, RR 0.20, p = 0.49, treatment 0 of 38 (0.0%), control 2 of 40 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7, dyspnea.
risk of no recovery, 57.9% lower, RR 0.42, p = 0.010, treatment 8 of 38 (21.1%), control 20 of 40 (50.0%), NNT 3.5, day 5, dyspnea.
risk of no recovery, 47.4% lower, RR 0.53, p = 1.00, treatment 1 of 38 (2.6%), control 2 of 40 (5.0%), NNT 42, day 7, fever.
risk of no recovery, 47.4% lower, RR 0.53, p = 0.25, treatment 5 of 38 (13.2%), control 10 of 40 (25.0%), NNT 8.4, day 5, fever.
risk of no recovery, 66.1% lower, RR 0.34, p = 1.00, treatment 0 of 38 (0.0%), control 1 of 40 (2.5%), NNT 40, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7, sore throat.
risk of no recovery, 47.4% lower, RR 0.53, p = 0.68, treatment 2 of 38 (5.3%), control 4 of 40 (10.0%), NNT 21, day 5, sore throat.
risk of no recovery, 29.8% lower, RR 0.70, p = 0.17, treatment 16 of 38 (42.1%), control 24 of 40 (60.0%), NNT 5.6, day 7, cough.
risk of no recovery, 7.1% lower, RR 0.93, p = 0.56, treatment 30 of 38 (78.9%), control 34 of 40 (85.0%), NNT 17, day 5, cough.
risk of no recovery, 21.1% lower, RR 0.79, p = 0.77, treatment 6 of 38 (15.8%), control 8 of 40 (20.0%), NNT 24, day 7, myalgia.
risk of no recovery, 38.1% lower, RR 0.62, p = 0.16, treatment 10 of 38 (26.3%), control 17 of 40 (42.5%), NNT 6.2, day 5, myalgia.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tehrani et al., 15 Jun 2022, Randomized Controlled Trial, Iran, peer-reviewed, mean age 52.5, 5 authors, study period April 2021 - September 2021, average treatment delay 5.29 days, trial IRCT20211004052664N1.
Contact: amirrezakeyvanfar@yahoo.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit